HIV and CD4: Viral Entry, Opportunistic Infections and Treatment | 感染 | OET Music

Dr Allison Lu · Pip & Barnaby · Medical English

本頁提供本曲完整英文歌詞與影片搭配的繁中醫學提示。歌詞保留原演唱文字;遇到過度簡化或舊門檻,請搭配下方提示與原始資料閱讀。這是概念學習材料,不替代個別醫療評估。

Lyrics · 完整歌詞

Human immunodeficiency virus exploits cells central to adaptive immunity,
converting their molecular machinery into a means of viral replication.
Entry begins when the envelope glycoprotein gp120 binds the CD4 receptor.
A conformational change then exposes the co-receptor binding site.
Macrophage-tropic strains use CCR5, whereas T-cell-tropic strains use CXCR4,
and gp41 drives fusion of the viral and cellular membranes.
Reverse transcriptase copies the RNA genome into DNA,
and integrase inserts it into the host chromosome as a provirus.
People homozygous for the CCR5 delta-32 deletion resist R5 strains,
and maraviroc mimics that deletion pharmacologically.
Years of chronic viraemia follow,
during which billions of virions are produced daily
and CD4 cells are progressively depleted.

Diagnosis depends on knowing what each assay can and cannot see.
The fourth-generation antigen and antibody immunoassay is highly sensitive but not confirmatory,
so a reactive result requires a differentiation assay
or Western blot before notification.
In acute infection,
antibody and even p24 antigen may be absent for the first weeks.

Only HIV RNA reliably detects this window,
and it should be requested whenever a compatible illness follows a recent exposure.

All reactive HIV screening tests require a confirmatory assay,
and acute infection is detected by HIV RNA rather than antibody.
Is the CD4 count below 200?
Then Pneumocystis prophylaxis with co-trimoxazole begins,
and below 100 the same drug covers Toxoplasma.
On treatment,
an undetectable viral load sustained for six months means the virus cannot be transmitted
sexually.
Lucid rule for tuberculosis:
start antiretrovirals within two weeks when the CD4 count is below 50,
but wait four to eight weeks in meningitis.


The CD4 count is a clock,
and each threshold uncovers a different pathogen.
Below 200 cells per microlitre, Pneumocystis pneumonia appears,
prevented and treated with co-trimoxazole.
Below 100, Toxoplasma encephalitis and cryptococcal meningitis emerge.
Below 50, cytomegalovirus retinitis and disseminated Mycobacterium avium complex follow.
Tuberculosis, candidiasis, zoster and Kaposi sarcoma can occur at any count.
A CD4 count below 200 defines AIDS by itself.
Non-Hodgkin lymphoma, Kaposi sarcoma and invasive cervical cancer are AIDS-defining,
whereas Hodgkin lymphoma, although more frequent, is not.

Antiretroviral therapy should start as soon as possible after diagnosis,
regardless of CD4 count.
Current Australian guidance prefers an integrase inhibitor such as bictegravir combined with emtricitabine
and tenofovir alafenamide.
Sustained suppression restores CD4 cells and eliminates sexual transmission.
The PARTNER studies recorded no linked transmissions from partners with an undetectable viral load,
the basis of undetectable equals untransmittable.
Without treatment,
vertical transmission occurs in about 25 to 30 per cent of pregnancies.
With suppressive therapy it falls below one per cent.

Tuberculosis co-infection demands sequencing.
Tuberculosis treatment starts first,
and antiretroviral therapy follows within two weeks
when the CD4 count is below 50.
At higher counts it may be started within eight weeks,
but tuberculous meningitis is the exception.
There,
therapy is deferred for four to eight weeks
because intracranial immune reconstitution raises mortality.
Rifampicin, a potent CYP3A4 inducer, renders boosted protease inhibitors sub-therapeutic.
Rifabutin, or an alternative regimen, is substituted.

All reactive HIV screening tests require a confirmatory assay,
and acute infection is detected by HIV RNA rather than antibody.
Is the CD4 count below 200?
Then Pneumocystis prophylaxis with co-trimoxazole begins,
and below 100 the same drug covers Toxoplasma.
On treatment,
an undetectable viral load sustained for six months means the virus cannot be transmitted
sexually.
Lucid rule for tuberculosis:
start antiretrovirals within two weeks when the CD4 count is below 50,
but wait four to eight weeks in meningitis.

Medical Notes · 醫學學習提示

  1. HIV主要侵襲CD4細胞,影響適應性免疫
  2. 病毒利用宿主細胞機制複製
  3. 包膜gp120先與CD4受體結合
  4. 結構改變後,可結合共同受體
  5. R5使用CCR5、X4使用CXCR4;細胞嗜性並非完全二分
  6. 病毒gp41促進膜融合
  7. 反轉錄酶將病毒RNA轉為DNA
  8. 整合酶將病毒DNA嵌入宿主染色體
  9. CCR5Δ32同型合子可抵抗R5,並非免疫所有HIV
  10. Maraviroc阻斷CCR5;不是基因刪除,須先測嗜性
  11. 未治療感染可持續多年;ART可抑制病毒
  12. 未治療時病毒持續大量複製,數量因人而異
  13. CD4可逐漸下降;有效治療可改善免疫功能
  14. 理解檢驗標的與空窗期,才能判讀結果
  15. 第四代篩檢同測抗原與抗體,陽性仍須補充檢驗
  16. 依當地流程,以分型檢驗與核酸檢驗確認
  17. Western blot屬舊流程;通報須依當地規範
  18. 急性感染初期,常規檢驗可能尚未陽性
  19. 抗體及p24抗原在極早期可能未能測出
  20. RNA可較早檢出;極早期陰性仍不能完全排除
  21. 近期暴露且疑似急性感染:加驗RNA並安排複驗
  22. 篩檢有反應不等於已確診,須完成確認流程
  23. 急性感染疑慮時加驗RNA,不只依賴抗體
  24. CD4<200提示肺囊蟲風險;預防還須看ART與病毒量
  25. 未用或正開始ART且CD4<200:考慮TMP-SMX預防
  26. 弓形蟲預防:IgG陽性且CD4<100,常用TMP-SMX
  27. 規律接受ART,並持續追蹤病毒量
  28. 持續病毒抑制且規律用藥,可避免性傳播
  29. U=U適用性傳播;不能直接推論哺乳零風險
  30. 合併結核時,抗結核與ART須協調時序
  31. 非結核腦膜炎且CD4<50:抗結核後兩週內ART
  32. 結核腦膜炎須個別延後ART,指引時機有差異
  33. CD4數值反映免疫狀態,不是疾病倒數計時器
  34. 感染風險隨免疫低下增加,門檻並非絕對
  35. CD4<200時肺囊蟲肺炎風險增加
  36. TMP-SMX可用於預防或治療,兩者劑量不同
  37. CD4<100:注意弓形蟲腦炎及隱球菌感染
  38. CD4<50:注意CMV視網膜炎與播散性MAC
  39. 結核、帶狀疱疹等可在不同CD4數值發生
  40. 已確認HIV者,CD4<200符合AIDS分期標準
  41. 特定淋巴瘤、卡波西肉瘤、侵襲性子宮頸癌屬定義疾病
  42. 何杰金淋巴瘤風險升高,但非AIDS定義疾病
  43. 原則上儘早啟動ART;部分中樞感染例外
  44. ART適用所有CD4數值,不必等待免疫惡化
  45. Bictegravir搭配FTC與TAF是常用初始方案之一
  46. 依腎功能、B肝共感染及藥物交互作用選擇
  47. 持續抑制病毒通常可改善CD4,並避免性傳播
  48. PARTNER研究中,病毒抑制組未見伴侶間連結性傳播
  49. 測不到=不經性接觸傳染,仍需規律用藥與追蹤
  50. 未接受治療時,母嬰傳播風險明顯上升
  51. 風險依妊娠、分娩與哺乳情境而異
  52. 孕產期有效ART及嬰兒預防,可使風險降至約1%以下
  53. 合併結核需要處理治療時序與藥物交互作用
  54. 先啟動有效抗結核治療
  55. 非腦膜炎且嚴重免疫低下:兩週內接續ART
  56. 此兩週建議適用CD4<50的非結核腦膜炎病例
  57. CD4≥50且非腦膜炎:通常抗結核後二至八週內ART
  58. 結核性腦膜炎的ART時機需特別評估
  59. 需由感染科團隊評估神經狀態
  60. 原曲四至八週並非各指引通用的固定等待期
  61. 避免顱內免疫重建發炎;依感染控制與指引決定
  62. Rifampicin誘導代謝,可能大幅降低加強型PI濃度
  63. 改用Rifabutin或替代方案,仍須核對劑量與交互作用
  64. 篩檢反應性結果須依流程確認
  65. 疑似急性感染加驗RNA,必要時複驗
  66. CD4<200需評估肺囊蟲預防,不只看單一數值
  67. 已用ART:CD4<100,或100–200且病毒量持續可測時預防
  68. 弓形蟲IgG陽性且CD4<100,TMP-SMX可兼顧預防
  69. 規律ART與追蹤是持續病毒抑制的關鍵
  70. 維持病毒抑制時,HIV不經性接觸傳播
  71. U=U的零風險結論限定性傳播
  72. 結核合併HIV:時序與交互作用都要評估
  73. 非結核腦膜炎且CD4<50:兩週內啟動ART
  74. 結核腦膜炎受控且治療至少兩週後,再評估ART時機

References